GOVX

GeoVax LabsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.90

-9.5% vs current

Most likely

Base case

45%

Probability

Target price

$1.05

-50.0% vs current

B-

Bear case

30%

Probability

Target price

$0.40

-81.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

This T+1 follow-up improves primary-source support but not conviction. The April 15, 2026 8-K and earnings release clearly refreshed the operating story, yet independent post-print reaction remains thin and no usable analyst revision set surfaced. Market tone stayed cautious: the stock closed at $1.28 on April 15, 2026, versus an anchor price of $1.10 on April 28, 2026, implying the update was overshadowed by runway and dilution concerns rather than embraced as a clean inflection. News flow is active but still heavily company-driven, so this remains a monitoring-style setup rather than a high-conviction turn.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystRunway and financing resolution is likely needed before the GEO-MVA milestone arrivesHigh impact

The 2025 10-K says GeoVax believed existing cash and cash equivalents were sufficient only into mid-second quarter 2026, while also noting substantial doubt about the company’s ability to continue as a going concern; even after February and March 2026 financing actions, proceeds discussed in the filing were modest relative to cash burn [#10-K-2026-04-15]. This makes financing the most immediate stock-moving variable.

2026-09-30eventGEO-MVA Phase 3 start remains the key post-earnings operational milestoneHigh impact

On April 15, 2026 the company said GEO-MVA is its most advanced program, that EMA scientific advice supports a streamlined path, that cGMP manufacturing and fill-finish are complete, and that a pivotal Phase 3 immuno-bridging study is planned for the second half of 2026 [#PR-2026-04-15] [#8-K-2026-04-15]. If execution holds, this is the clearest route to a valuation re-rate; if it slips, the thesis weakens quickly.

2026-12-31catalyst2026 GEO-CM04S1 readouts and Gedeptin partnering can add optionality, but they are back-end loadedHigh impact

The April 15, 2026 business update said GEO-CM04S1 data readouts are expected during 2026 and Gedeptin is being prepared for a Phase 2 strategy with partnership discussions still part of the plan [#PR-2026-04-15]. These programs support upside optionality, but near-term monetization is less visible than for GEO-MVA and remains funding-dependent.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology